Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
12 search results for:

BAFF/BLyS inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 29-01-2019 | Lupus nephritis | Editorial | Article

    Emerging therapies for lupus nephritis

    Anti-B lymphocyte stimulator Belimumab, a mAb targeting BAFF (also known as B lymphocyte stimulator [BLyS]), which is currently approved for extra-renal SLE, is under investigation in LN (BLISS-LN, NCT01639339).

    Author:
    Lara El Khoury, Richard Furie
  2. 29-01-2019 | Lupus nephritis | Highlight | Teaser
    Expert opinion editorial

    Emerging therapies for lupus nephritis

    Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

  3. 03-04-2018 | Systemic lupus erythematosus | News | Article

    Blisibimod SLE trial fails to reach primary endpoint

    An earlier, phase II trial involving blisibimod also failed to meet its primary efficacy endpoint but upheld observations in phase III trials of targeted BAFF inhibitors showing greater treatment effect among certain patients, namely those with higher disease activity, greater corticosteroid doses, antibodies against double stranded (ds)DNA, and low complement C3 or 4.

    Published in:
    Ann Rheum Dis 2018; Advance online publication
  4. 06-03-2018 | Systemic lupus erythematosus | Review | Article

    Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: A review of observational clinical-practice-based studies

    Trentin F et al. Clinic Rev Allerg Immunol 2018; Advance online publication. doi: 10.1007/s12016-018-8675-2

  5. 26-04-2018 | Systemic lupus erythematosus | News | Article

    Promising results for subcutaneous belimumab in subset of SLE patients

    Treatment with subcutaneous belimumab may be beneficial for patients with SLE who are hypocomplementemic and positive for antibodies against double-stranded DNA, subgroup analyses of a phase III trial suggest.

    Published in:
    Arthritis Rheumatol 2018; Advance online publication
  6. 09-03-2017 | Systemic lupus erythematosus | Article

    Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

    The OBSErve Canada Study results, reported here, deliver insights into the overall pattern of systemic lupus erythematosus care, characteristics of patients receiving belimumab, and clinical outcomes following treatment. Touma Z et al. Rheumatol Int 2017;37:865–873. doi:10.1007/s00296-017-3682-9

  7. 06-03-2017 | Systemic lupus erythematosus | Review | Article

    Novel treatments in lupus

    Systemic lupus erythematosus treatment has been dominated by non-specific immunosuppressive approaches. New treatments offer the potential to target the disease more specifically and are reviewed herein. Kyttaris VC. Curr Rheumatol Rep 2017;19:10. doi:10.1007/s11926-017-0638-8

  8. 30-09-2016 | Systemic lupus erythematosus | Review | Article

    An update on treatment and management of pediatric systemic lupus erythematosus

    Childhood-onset systemic lupus erythematosus (SLE) requires a multidisciplinary approach due to the complexity of the disease. The authors review recommendations for the management of children with SLE. Thakral A & Klein-Gitelman MS. Rheumatol Ther 2016;3:209–219. doi:10.1007/s40744-016-0044-0

  9. 06-07-2016 | Systemic lupus erythematosus | Review | Article

    Clinical pharmacokinetics and pharmacodynamics of biologic therapeutics for treatment of systemic lupus erythematosus

    Sherwin et al. summarize the pharmacokinetic and pharmacodynamic characteristics of biologic agents that are approved, off-label, or in the pipeline for systemic lupus erythematosus. Yu T et al. Clin Pharmacokinet 2017;56:107–125. doi:10.1007/s40262-016-0426-z

  10. 10-04-2016 | Systemic lupus erythematosus | Book Chapter | Article

    Innovative therapies in systemic lupus erythematosus

    New biological agents have the potential to revolutionize the treatment of systemic lupus erythematosus. This chapter evaluates data on novel therapeutic targets that are showing promise. Fenoglio R, Fervenza F, Roccatello D. In: Connective Tissue Disease . Edited by Roccatello D & Emmi L. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-24535-5_17

  11. 02-02-2016 | Systemic lupus erythematosus | Review | Article

    Prevention and treatment of bone disease in systemic lupus erythematosus

    Lin and Grossman highlight a number of recommendations for the prevention and treatment of comorbid bone disease in systemic lupus erythematosus patients. Lin T & Grossman J. Curr Treat Options in Rheum 2016;2:21–35. doi:10.1007/s40674-016-0034-y

  12. 11-07-2018 | Pediatric | Review | Article

    Pediatric Rheumatology Collaborative Study Group: Over four decades of pivotal clinical drug research in pediatric rheumatology

    Brunner HI et al. Pediatr Rheumatol 2018; 16: 45. doi: 10.1186/s12969-018-0261-x

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.